Monday, Oct 30, 1989
South San Francisco, Calif. -- October 30, 1989 --Beginning November 1, Hoechst's West German subsidiary, Behringwerke, will join Boehringer-Ingelheim's subsidiary, Dr. Karl Thomae GmbH, in promoting and distributing t-PA, blood clot dissolving agent. Behringwerke distributes streptokinase, a t-PA competitor.
Boehringer-Ingelheim is Genentech's international marketing partner for t-PA, and has been marketing the product in Germany under the trade name Actilyse®, t-PA. The drug was approved for the treatment of acute myocardial infarction in that country in October 1987. Hoechst markets streptokinase in Germany, the U.S. and many other countries.
The two companies said they entered into the agreement to expand their combined presence in the German thrombolytics market, and to respond to the growing need for reliable information and advice on this important heart attack treatment option.
"The combined marketing strength of our partner, Boehringer-Ingelheim, and Hoechst is an important event for t-PA," said Kirk Raab, President and Chief Operating Officer for Genentech. "We welcome Hoechst's expertise in the area of thrombolytic therapy and look forward to further expansion of that market in Germany."
Actilyse® (alteplase, t-PA) is used to dissolve blood clots in patients suffering heart attacks. It was developed and is marketed in the U.S., as Activase®, t-PA, by Genentech.
Genentech, Inc. is a biotechnology company focusing on the development, manufacture and marketing of pharmaceutical products produced by recombinant DNA technology.
# # #